Celecoxib (Synonyms: SC58635, YM177) |
Catalog No.GC14475
One-Click Copy Product Info
|
Celecoxib is a highly selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 40nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 169590-42-5
Sample solution is provided at 25 µL, 10mM.
Celecoxib is a highly selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 40nM[1]. Celecoxib is a selective nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat acute pain, osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis and ankylosing spondylitis (AS)[2]. Celecoxib has strong anti-tumor activity and can prevent and treat a variety of cancers such as pancreatic cancer, breast cancer, ovarian cancer, and non-small cell lung cancer[3]. Celecoxib can prevent the occurrence of colorectal adenomatous polyps[4].
In vitro, Celecoxib (0.8, 2.0, 4.0, 8.0µg/mL) treated tenocytes for 24h dose-dependently inhibited cell viability and migration, but did not change cell morphology or cause cell necrosis[5]. Celecoxib (1-100μM) treated human osteoblasts for 24h, inhibited cell proliferation in a dose-dependent manner and caused an increase in intracellular Ca2+ concentration[6].
In vivo, Celecoxib (100mg/kg) was orally administered to mice with lung cancer model and unilateral lung resection, inhibiting lung cancer metastasis and the increase in plasma PGE2 levels[7]. Celecoxib (10, 20mg/kg) was orally administered to rats with gastric cancer model, significantly reducing the incidence and growth of gastric cancer in rats[8].
References:
[1] Cao H, Yu R, Choi Y, et al. Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation[J]. Pharmacological research, 2010, 61(6): 519-524.
[2] Frampton J E, Keating G M. Celecoxib: a review of its use in the management of arthritis and acute pain[J]. Drugs, 2007, 67: 2433-2474.
[3] Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer[J]. Cancer letters, 2013, 332(2): 313-324.
[4] Arber N, Eagle C J, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps[J]. New England Journal of Medicine, 2006, 355(9): 885-895.
[5] Tsai W C, Hsu C C, Chou S W, et al. Effects of celecoxib on migration, proliferation and collagen expression of tendon cells[J]. Connective tissue research, 2007, 48(1): 46-51.
[6] Wang J L, Lin K L, Chen J S, et al. Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts[J]. Biochemical pharmacology, 2004, 67(6): 1123-1130.
[7] Zhang S, Da L, Yang X, et al. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway[J]. Toxicology letters, 2014, 225(2): 201-207.
[8] Hu P J, Yu J, Zeng Z R, et al. Chemoprevention of gastric cancer by celecoxib in rats[J]. Gut, 2004, 53(2): 195-200.
| Cell experiment [1]: | |
|
Cell lines |
Tendon cells |
|
Preparation Method |
Cells were first seeded into 24-well flat-bottomed culture plates. Celecoxib was then added to the culture dish at dosages of 0, 0.8, 2.0, 4.0, and 8.0µg/mL. Then 24h after Celecoxib was added to cells, cells were observed under microscope and then MTT assay was performed. |
|
Reaction Conditions |
0.8, 2.0, 4.0, 8.0µg/mL; 24h |
|
Applications |
Celecoxib dose-dependently inhibited tendon cell viability and migration, but no cell necrosis or changes in cell morphology were observed. |
| Animal experiment [2]: | |
|
Animal models |
Female BALB/c nude mice |
|
Preparation Method |
Mice were randomly divided into the following five treatment groups: control; mice were injected with PGE2 (1mg/kg); mice were injected with PGE2 (1mg/kg) and Celecoxib (100mg/kg); mice received pneumonectomy; mice received pneumonectomy and Celecoxib (100mg/kg). A549 cells were prepared as a suspension of 106 cells in 150µL saline and injected using a 29-gauge needle into the lateral tail vein under sterile conditions. Celecoxib (100mg/kg) was administered orally starting from the day before tumor cell injection until the mice were sacrificed. After the mice were sacrificed, the lungs were flushed with 5% picric acid solution. Lung metastasis was determined by counting the total number of metastatic nodules in each lung. |
|
Dosage form |
100mg/kg; p.o. |
|
Applications |
The metastasis of A549 cells in mice receiving unilateral pneumonec tomy was more than that in control mice, and treatment with Celecoxib inhibited this increase in metastases. The mean level of plasma PGE2 in mice receive ing unilateral pneumonectomy increased, and treatment with Celecoxib significantly inhibited the increase in PGE2 plasma level. |
|
References: |
|
| Cas No. | 169590-42-5 | SDF | |
| Synonyms | SC58635, YM177 | ||
| Chemical Name | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide | ||
| Canonical SMILES | CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F | ||
| Formula | C17H14F3N3O2S | M.Wt | 381.37 |
| Solubility | ≥ 19.1mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6221 mL | 13.1106 mL | 26.2213 mL |
| 5 mM | 524.4 μL | 2.6221 mL | 5.2443 mL |
| 10 mM | 262.2 μL | 1.3111 mL | 2.6221 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)